Therefore, to overcome the AKT-inhibitor-induced resistance to apoptosis in CRC, we aimed to evaluate the therapeutic effect of a decrease in nuclear β-catenin via the KY1022 treatment. The gene discussed is AKT1; the disease is colorectal carcinoma.